A Pennsylvania jury has been assembled to hear evidence in another trial involving Risperdal and gynecomastia. According to a report from The Legal Intelligencer, opening arguments began on June 20th, in the Philadelphia Court of Common Pleas, with the plaintiff’s attorney asserting that the drug’s manufacturers concealed data linking Risperdal to the growth of excess breast tissue in young boys.

However, attorneys for Johnson & Johnson and its Janssen Pharmaceuticals unit insisted that the plaintiff’s doctor was well aware of the risks associated with Risperdal, but chose to continue treatment because the antipsychotic medication was “the only thing that ever worked for him.”

According to court documents, the plaintiff began taking Risperdal in 2003, when he was five-years-old to treat severe psychiatric problems that included violent and oppositional behavior. By 2004, the Tennessee native had experienced abnormal breast growth, and tests revealed elevated levels of prolactin in his blood. Prolactin is a hormone associated with breast development and lactation in women.

During opening remarks, the plaintiff’s attorney told jurors that Janssen’s own internal documents proved the company took steps to conceal the true risk Risperdal posed in regards to male breast growth.

“They say it’s rare, but, under the definitions, it’s frequent,” he said. “What they want to do, to make the business plan work, is to … use the data, as a business opportunity, to help the doctors prescribe” Risperdal.

In 2006, additional information about Risperdal and gynecomastia was added to the drug’s label.

“This family did not deserve to have the people they came to for help withhold information about the risks,” the attorney said. “The family did not know in 2003, 2004 and 2005, what these internal documents showed, and because of that Andrew has these female breasts.”

Risperdal Gynecomastia Trials

Court documents indicate that Johnson & Johnson and Janssen have been named in more than 1,700 similar Risperdal lawsuits, all of which are centralized in a mass tort program underway in Philadelphia.

Since 2015, a number of Risperdal gynecomastia cases have gone to trial in Philadelphia, two of which ended with verdicts of $2.5 million and $1.75 million for the plaintiffs. The jury hearing a fourth case declined to award any damages to the plaintiff, after determining that the drug did not cause his breast growth. However, those jurors also found that Risperdal’s manufacturers were negligent in failing to warn that the drug could cause excessive breast development in boys. A fifth case settled in May just before it was scheduled to go to trial.

Schedule a Risperdal Lawsuit Review

There is still time to become involved in this litigation. If you would like to learn more about filing a Risperdal lawsuit for gynecomastia, the nationwide law firm of Bernstein Liebhard LLP can help. To arrange for a free case review, please call 877-779-1414.

Published June 21, 2016 by